scispace - formally typeset
Open AccessJournal ArticleDOI

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

TLDR
This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.
Abstract
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

read more

Citations
More filters
Journal ArticleDOI

REGEN-COV ® antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification.

TL;DR: In this paper, a two-part bioanalytical strategy was implemented to ensure the anti-SARS-CoV-2 monoclonal antibody cocktail, REGEN-COV (RONAPREVE® outside the USA).
Posted ContentDOI

Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70, Lyon, France, August to December 2020

TL;DR: In this paper, the authors report the implementation of a two-step strategy enabling to detect SARS-CoV-2 variants carrying H69-V70 deletion, which resulted in a false negative result for the spike target of a three-target RT-PCR assay.
Journal ArticleDOI

Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2

TL;DR: The current study increases the understanding of ACE inhibition by MLN-4760 and how it modulates the conformational properties of ACE2 and its interaction with the receptor-binding domain (RBD) of SARS-CoV-2.
Journal ArticleDOI

Persistent SARS-CoV-2 Infection in a Patient With Non-hodgkin Lymphoma: Intra-Host Genomic Diversity Analysis

TL;DR: The findings show the evolution of the intra-host variability during the course of a long-lasting infection with severe acute respiratory syndrome coronavirus 2.
Journal ArticleDOI

Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants

TL;DR: Because microalgal cells contain a rigid cell wall that could act as a natural encapsulation to protect the recombinant proteins from the aggressive environment of the stomach, this feature could be used for the rapid production and edible targeted delivery of S-glycoprotein and soluble ACE2 for the treatment/inhibition of SARS-CoV-2.
References
More filters
Journal ArticleDOI

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

TL;DR: Cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein of SARS-CoV-2 are presented, providing important insights into the molecular basis for coronavirus recognition and infection.
Journal ArticleDOI

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

TL;DR: The crystal structure of the C-terminal domain of SARS-CoV-2 (SARS- coV- 2-CTD) spike (S) protein in complex with human ACE2 (hACE2) is presented, which reveals a hACE2-binding mode similar overall to that observed for SARS -CoV.
Journal ArticleDOI

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Related Papers (5)